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Aims This multicentre, randomized trial compared three strategies of AF ablation: ablation of complex fractionated elec-




Patients with drug-refractory, high-burden paroxysmal (episodes .6h ,.4 in 6 months) or persistent atrial ﬁbrillation
(AF) were enrolled at eight centres. Patients (n ¼ 100) were randomized to one of three arms. For CFE alone (n ¼ 34),
spontaneous/induced AF was mapped using validated, automated CFE software and all sites ,120 ms were ablated until
AF termination/non-inducibility. For PVI (n ¼ 32), all four PV antra were isolated and conﬁrmed using a circular catheter.
For PVI þ CFE (n ¼ 34), all four PV antra were isolated, followed by AF induction and ablation of all CFE sites until AF
termination/non-inducibility. Patients were followed at 3, 6, and 12 months with a visit, ECG, 48 h Holter. Atrial ﬁbrilla-
tion symptoms were conﬁrmed by loop recording. Repeat procedures were allowed within the ﬁrst 6 months. The
primary endpoint was freedom from AF .30 s at 1 year. Patients (age 57+10 years, LA size 42+6m m )w e r e
35% persistent AF. In CFE, ablation terminated AF in 68%. Only 0.4 PVs per patient were isolated as a result of
CFE. In PVI, 94% had all four PVs successfully isolated. In PVI þ CFE, 94% had all four PVs isolated, 76% had inducible
AF with additional CFE ablation, with 73% termination of AF. There were signiﬁcantly more repeat procedures in the
CFE arm (47%) vs. PVI (31%) or PVI þ CFE (15%) (P ¼ 0.01). After one procedure, PVI þ CFE had a signiﬁcantly higher
freedom from AF (74%) compared with PVI (48%) and CFE (29%) (P ¼ 0.004). After two procedures, PVI þ CFE still
had the highest success (88%) compared with PVI (68%) and CFE (38%) (P ¼ 0.001). Ninety-six percent of these
patients were off anti-arrhythmics. Complications were two tamponades, no PV stenosis, and no mortality.
Conclusion In high-burden paroxysmal/persistent AF, PVI þ CFE has the highest freedom from AF vs. PVI or CFE alone after one
or two procedures. Complex fractionated electrogram alone has the lowest one and two procedure success rates
with a higher incidence of repeat procedures.
ClinicalTrials.gov identiﬁer number NCT00367757.
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Elimination of the triggers of atrial ﬁbrillation (AF) through electri-
cal isolation of the pulmonary veins (PVs) has been the basis of
most AF ablation approaches to date in both the paroxysmal and
persistent AF populations.
1 Studies have correlated outcome of
ablation directly with the degree of PV isolation in predominantly
paroxysmal AF patients.
2 However, alternative approaches to AF
ablation have been proposed, speciﬁcally focused on modifying
the substrate responsible for AF perpetuation, as opposed to
just eliminating the triggers for AF initiation.
Speciﬁcally, atrial electrograms (EGMs) demonstrating continu-
ous fractionation and/or very short cycle length (CL) during AF
may represent critical pivot points or rotors that are responsible
for the maintenance of AF.
3 These so-called complex fractionated
electrograms (CFE) may therefore serve as a potential target of
ablation. Previous data have shown that targeting CFE may result
in AF slowing, regularization, and termination.
4 These acute
changes in AF may correlate with long-term freedom from AF
recurrence, but the data are very limited and restricted to single-
centre experiences.
4–6 Furthermore, these studies have targeted
CFE by visual inspection alone, but identiﬁcation of CFE can be
very challenging and subjective, limiting the utility of CFE as an abla-
tion endpoint. Automated mapping algorithms have been designed
and validated to identify CFE regions, and have been shown to
improve ablation outcomes.
7,8
Whether trigger-based ablation strategies, such as pulmonary
vein isolation (PVI), or substrate-based strategies, such as CFE,
should be used alone or in combination is not well known. Com-
parative data are limited to single-centre reports,
9–12 and most of
these used visual identiﬁcation of CFE as opposed to a standar-
dized, automated approach. Thus, the purpose of this prospective,
randomized, multicentre study was to compare three strategies of
AF ablation using a standardized, validated approach to substrate




We conducted a prospective, multicentre, randomized trial. The trial
was registered with ClinicalTrials.gov on 22 August 2006 with the
identiﬁer number NCT00367757. Enrolment commenced in August
2006. Patients were randomized 1:1:1 to one of three AF ablation
strategies: CFE alone, PVI alone, or combined PVI þ CFE. Enrolment
occurred at eight centres (four in Canada and four in Europe). All
participating operators were experienced AF ablation specialists
(.100 AF ablations per operator/year). Because of the nature of
the procedures, operators were not blinded to the randomization,
but patients were (single-blind design). Randomization was done by
random allocation centrally at the clinical trial centre and was strati-
ﬁed by site. Allocation concealment was maintained at all sites by
sequentially numbered, opaque, sealed envelopes. Data were col-
lected, managed, and analysed by a central, independent monitoring
group with a restricted access database. Written informed consent
was obtained from each participant prior to study inclusion. The
study protocol was approved by the institutional ethics review
board at each institution.
Patient population
Patients undergoing ﬁrst-time ablation for symptomatic AF that was
refractory to at least one anti-arrhythmic drug were enrolled. At
least one episode of AF had to be documented by ECG or Holter
within 12 months of randomization in the trial. All patients had to
have high-burden paroxysmal AF or persistent AF. Deﬁnitions of par-
oxysmal and persistent AF follow those outlined in the ACC/AHA/ESC
Guidelines for the Management of Patients with AF.
13 High-burden
paroxysmals were included in the study because of data suggesting
that even paroxysmal AF patients with greater amounts of arrhythmia
may have abnormal atrial substrate changes which may need to be tar-
geted in addition to PV triggers.
7,14 Speciﬁcally, ‘high-burden’ paroxys-
mal AF was deﬁned as .four self-terminating episodes within 6
months, two of which were at least 6 h in duration within the last
year. Persistent AF was deﬁned as episodes sustained for .7 days,
but less than 12 months, requiring termination by pharmacological
or electrical cardioversion. Detailed inclusion and exclusion criteria
for patients are outlined in Table 1.
Catheter ablation strategies
All patients underwent catheter ablation using radiofrequency (RF)
energy. Patients were all anticoagulated with warfarin to maintain an
international normalized ratio (INR) of 2–3 for at least 4 weeks
prior to the procedure as outlined in the inclusion criteria. Patients
................................................................................
Table 1 Study inclusion and exclusion criteria
Inclusion criteria
Patients age 18 or greater
Patients with a ‘high burden’ of paroxysmal atrial ﬁbrillation or
persistent atrial ﬁbrillation. ‘High burden’ paroxysmal atrial
ﬁbrillation will be deﬁned as more than four episodes within 6
months that are self-terminating, with at least two episodes .6h
by symptoms within the last year. Persistent atrial ﬁbrillation will
be deﬁned as a sustained episode .7 days but ,12 months in
duration that was terminated by a non-ablative therapeutic
intervention (cardioversion or drug)
AF must be symptomatic and refractory to at least one
anti-arrhythmic medication
At least one episode of AF must have been documented by ECG or
Holter within 12 months of randomization in the trial
Patients must be on continuous anticoagulation with warfarin (INR
2–3) for .4 weeks prior to the ablation
Patients must be able and willing to provide written informed
consent to participate in the clinical trial
Exclusion criteria
Patients with permanent atrial ﬁbrillation
Patients with AF felt to be secondary to an obvious reversible cause
Patients with inadequate anticoagulation as deﬁned in the inclusion
criteria
Patients with left atrial thrombus on transesophageal echo prior to
the procedure
Patients with contraindications to systemic anticoagulation with
heparin or coumadin
Patients who have previously undergone atrial ﬁbrillation ablation
Patients with left atrial size .55 mm
Patients who are or may potentially be pregnant
AF, atrial ﬁbrillation.
STAR AF trial 1345were not ablated, if transesophageal echocardiography (TEE) prior to
the procedure demonstrated left atrial thrombus. All patients except
those at one centre (n ¼ 9) underwent pre-procedural TEE. All pro-
cedures were performed in the fasting state under conscious sedation
or general anaesthesia depending on each participating centre. Anti-
arrhythmic medications were stopped at least ﬁve half-lives prior to
the procedure, except amiodarone, which was stopped at least 8
weeks prior.
All procedures were performed via transseptal access to the left
atrium (LA). After transseptal access, patients were anticoagulated
with intravenous heparin to maintain an ACT of .300 s. A multipolar
catheter (minimum eight bipoles) was placed in the coronary sinus
(CS). A decapolar, circular mapping catheter was utilized for both
mapping and conﬁrmation of PV isolation (according to the random-
ized ablation strategy). Ablation was performed using a 3.5 mm
irrigated-tip ablation catheter (Therapy Cool Path, St Jude Medical,
Minneapolis, MN, USA). Power was limited to 40 W (30 W on the
posterior wall) with an irrigation ﬂow rate of 30 mL/min. Prior to
irrigated-tip catheter availability, the ﬁrst 21 patients were ablated
using an 8 mm non-irrigated-tip ablation catheter (Therapy Dual 8,
St Jude Medical, Minneapolis, MN, USA) using a maximum power of
60 W (40 W on the posterior wall) and temperature of 508C. These
patients were evenly distributed across the three study arms. Continu-
ous impedance monitoring was used and RF was discontinued if a
.10 V impedance rise was observed. All procedures were guided
using an electroanatomical mapping system (Ensite NavX, St Jude
Medical, Minneapolis, MN) to construct a three-dimensional shell of
the PVs, LA, CS, and right atrium (RA) if required, using the circular
mapping and/or ablation catheters. Post-ablation, all study maps and
data were copied to DVD and sent to the central database for
analysis/adjudication. The speciﬁcs of each of the three ablation
strategies were as follows.
Trigger-based strategy (pulmonary vein isolation)
Pulmonary vein isolation was performed using a standard wide circum-
ferential PV antral isolation approach. Through transseptal accesses,
the circular mapping and ablation catheters were advanced into the
LA, followed by reconstruction of the LA, PV, and CS anatomy using
the mapping system. The ostia and antra of the PVs were deﬁned by
examination of the 3D electroanatomical shell, impedance, and signal
mapping as the catheter was pulled back from inside the vein, and
when available, intracardiac echocardiography. The circular mapping
catheter was then placed sequentially within each of the four PV
antra to record PV potentials. Circumferential RF lesions were then
placed at least 1–2 cm outside of the PV ostia to encircle and electri-
cally isolate each of the PV antra while avoiding PV stenosis. Because of
the narrow ridge of tissue between the anterior aspect of the left
superior PV and the left atrial appendage, ablation was allowed
within 1 cm of the ostium of the left superior PV to encircle and
isolate this vein. As each antrum was encircled, the circular catheter
was used to conﬁrm electrical isolation. Radiofrequency isolation of
the PV antrum was considered complete when all PV potentials
within each antrum were abolished, as recorded by the circular
mapping catheter during sinus rhythm or CS pacing. Ablation tags
were only placed on the LA shell, if RF energy had been applied for
more than 20 s at a given spot. Rechecking of all the antra was per-
formed at the end of the ablation procedure to conﬁrm the presence
of block (minimum 30 min wait after last ablation lesion). The goal was
to isolate all four PV antra for every patient. If the patient was in AF at
the end of the procedure, they were electrically cardioverted back to
sinus rhythm. Remapping of the PVs post-cardioversion was performed
to conﬁrm PV isolation. Termination and/or non-inducibility of AF
were not endpoints of this ablation strategy.
Substrate-based strategy (complex fractionated
electrograms)
The detailed technique for ablating CFE using the automated mapping
software has been described and validated previously.
7 In brief, if the
patient was not already in AF at the start of the procedure, AF was
induced by rapid atrial pacing from the distal tip of the CS catheter.
Pacing was performed at the shortest 1:1 atrial capture rate for up
to 15 s at a time, up to ﬁve times in a row, with 30 s between attempts.
If AF could not be sustained for longer than 1 min, an infusion of iso-
proterenol (causing an increase in baseline heart rate  50%, dose up
to 10 mcg/min) was used to sustain AF. Induced AF needed to persist
for .1 min prior to mapping for CFE.
Once in AF, CFE mapping using an automated algorithm (Ensite
NavX, St Jude Medical) was performed in the LA, CS, and RA.
Bipolar EGMs were obtained during AF by mapping with the circular
mapping catheter and/or the 3.5 mm tip ablation catheter. In areas
were the circular mapping catheter could not obtain good atrial
contact, mapping was supplemented using the 3.5 mm tip ablation
catheter. Bipolar recordings were ﬁltered at 30–500 Hz. The algor-
ithm measures the time between multiple, discrete deﬂections
(2dV/dT) in a local AF EGM recording over a speciﬁed length of
time (5 s) and then averages these inter-deﬂection time intervals to
calculate a mean CL of the local EGM during AF. This mean CL is
then projected onto the LA anatomical shell as a colour-coded
display. The shorter the CL, the more rapid and fractionated the
local EGM. Speciﬁcally for this study, regions with a mean CL of less
than 120 ms were deﬁned as ‘CFE’ based on previously published
data.
7,15 Selectable peak-to-peak EGM amplitude, EGM width, and
post-EGM refractory period were deﬁned to assist in algorithm deﬂec-
tion detection and have been previously validated (Table 2).
7 At the
start of the procedure, the baseline signal noise level was determined
and the peak-to-peak detection limit was set just above the noise level
(typically 0.03–0.05 mV) to avoid noise detection while allowing
detection of CFEs that are typically of very low amplitude
(,0.5 mV).
4 Deﬂection width and refractory criteria were set at
15–20 ms and 35–45 ms, respectively, to avoid double-counting indi-
vidual EGM deﬂections. To avoid including signals from bipoles that
Table 2 Recommended settings for automated
complex fractionated electrogram mapping algorithm
Peak-to-peak sensitivity (minimum detection
threshold, avoids detecting noise)
0.03–0.05 mV
EGM refractory period (avoids double-counting a
single EGM with multiple components)
35–45 ms
EGM width (avoids detection of broader,
far-ﬁeld EGMs)
15–20 ms
EGM segment length (total recording duration at
each point, obtains a mean CL for that point)
5s
Interpolation (maximum distance between points
which will be used to assign average values for
a vertex)
4–6mm
Internal/external projection (avoids collection of
EGMs from electrodes that are not in good
contact with map shell)
4–6mm
EGM, electrogram; CL, cycle length.
A. Verma et al. 1346were internal in the LA, the internal interpolation of the algorithm was
set at 4–6 mm to include only those signals obtained from bipoles with
good atrial shell contact. Width, refractory, and interpolation criteria
were set at 15 ms, 45 ms, and 4 mm respectively, as more validation
data became available over the course of the study; however, the vali-
dation data showed little change in sensitivity or speciﬁcity over the
narrow ranges speciﬁed above.
7,15
Complex fractionated electrogram sites deﬁned by the algorithm
(CL , 120 ms) were targeted for ablation. Regions with the shortest
CL were targeted ﬁrst, followed by longer CL regions (up to
120 ms). Ablation at a CFE site was continued until local EGM elimin-
ation which typically required 30–60 s of RF application. During abla-
tion of CFE sites, the mean atrial ﬁbrillation cycle length (AFCL) and
AF regularity were periodically measured from a selected CS record-
ing. As per previous technique,
7 the CS recording with the shortest
average CL was selected, and the same site was used for pre- and post-
ablation comparisons. Atrial ﬁbrillation cycle length was determined by
counting the number of discrete atrial EGMs over a 15 s recording (x)
and dividing 15 000 by x. The CS recording was also periodically exam-
ined to look for regularization to atrial ﬂutter (AFL) or atrial tachycar-
dia (AT) during CFE ablation. Termination rates of AF during CFE
ablation were also recorded. No intravenous anti-arrhythmics
were used during initial ablation to change AFCL or help regularize/
terminate AF. The endpoint for CFE ablation was (i) elimination of
all CFE sites in the LA, CS, and RA or termination of AF and (ii) non-
inducibility of AF post-ablation. If AF terminated as a result of CFE
ablation, an attempt was made to reinduce AF using the same standar-
dized protocol detailed in the ﬁrst paragraph of this section. If isopro-
terenol was used initially to maintain AF, then the same dose was used
for post-ablation induction. If the patient remained inducible for AF
(AF persisting.1 min), then further CFE ablation was performed in
the LA, CS, and RA until all CFE sites were eliminated or until AF
became non-inducible. If AF did not terminate after eliminating all
CFE sites, sinus rhythm was restored by electrical cardioversion. If
AF regularized to an AFL/AT, which did not terminate after all CFE
sites were ablated, the ﬂutter/tachycardia was mapped and ablated
or cardioverted electrically at the discretion of the investigator. At
the very end of the CFE procedure, investigators were also asked to
place the circular mapping catheter into each of the PVs to assess if
any of them had been incidentally isolated as a result of CFE ablation.
Combined strategy (pulmonary vein isolation 1 complex
fractionated electrograms)
Patients randomized to this arm ﬁrst underwent wide circumferential
PVI as described in the ‘trigger-based’ strategy above. The endpoint
was complete isolation of all four PVs documented by a circular
mapping catheter. Following completion of the PVI procedure, if the
patient was spontaneously in AF, mapping was performed in AF to
identify regions of CFE using the automated algorithm as described
in the ‘substrate-based’ strategy above. If the patient was not in AF
at the end of the PVI, AF induction was performed according to the
protocol described earlier with or without the use of isoproterenol.
If the patient was non-inducible, then no further ablation was per-
formed. If the patient was inducible (AF persisting .1 min), CFE
regions were mapped and ablated using the automated software to
the same endpoint as described in Substrate-based strategy section.
If AF did not terminate after mapping and ablation of all CFEs in the
LA, RA, and CS, the AF was electrically cardioverted and the pro-
cedure terminated. If AF regularized to an AFL/AT, which did not ter-
minate after all CFE sites were ablated, the ﬂutter/tachycardia was
mapped and ablated or cardioverted electrically at the discretion of
the investigator.
Repeat ablation procedures
Up to one additional ablation procedure was allowed by the protocol.
In order to keep patients on the same follow-up schedule, it was rec-
ommended that a repeat ablation be done no sooner than 3 months,
but less than 6 months after the initial procedure. The strategy used for
the second ablation procedure had to be identical to the initial ran-
domized strategy used in the ﬁrst procedure.
Follow-up
All patients were discharged home within 2 days following the pro-
cedure. Post-procedure, patients continued anticoagulation with war-
farin to maintain an INR of 2–3 for a minimum of 3 months. In all
patients, anti-arrhythmic medications were continued for 2 months
post-ablation and were chosen from one of sotalol, propafenone, ﬂe-
cainide, or dofetilide. Anti-arrhythmic medications were discontinued
in all patients after 2 months.
Patients were followed in the outpatient clinic of their respective
institutions at 3, 6, and 12 months post-ablation (+2 weeks for
each time point for follow-up). Monthly telephone interviews were
also done. A 12-lead ECG and 48 h Holter recording was done routi-
nely in all patients at each of the 3, 6, and 12 months follow-up visits.
External loop recorders (minimum 2 weeks) and/or transtelephonic
monitors were used to conﬁrm rhythms for any patient-reported
symptoms outside of the routine follow-ups. Interrogation of
implanted devices was also used, when applicable, to conﬁrm arrhyth-
mia recurrence. Recurrences were based upon patient reporting, loop,
Holter, device, and/or ECG detection. A ‘recurrence’ of atrial arrhyth-
mia was considered any episode lasting .30 s (symptomatic or asymp-
tomatic). A blanking period of 3 months after the initial ablation was
employed such that recurrences during this time were not counted.
1
Patients also had a routine spiral computed tomography or magnetic
resonance imaging of the chest within 6 months post-ablation to assess
for PV stenosis. Pulmonary vein stenosis was graded as mild if there
was ,50% narrowing, moderate if there was 50–70% narrowing,
and severe if there was .70% narrowing.
No patients were lost to follow-up and all underwent the required
outpatient visits and monitoring.
Although the HRS/EHRA/ECAS Expert Consensus Statement on
Catheter and Surgical Ablation of Atrial Fibrillation had not yet been
published at the time this protocol was designed, the follow-up was
consistent with the requirements of this document.
1
Study endpoints
The primary endpoint of the study was freedom from AF recurrence
from Months 3 to 12 post-ablation after one or two procedures on
and off anti-arrhythmic medications (excludes the pre-speciﬁed blank-
ing period from Months 0 to 3). Secondary endpoints included
freedom from any atrial arrhythmia recurrence, namely AF, AT, or
AFL after one and two procedures from Months 3 to 12 on and off
anti-arrhythmic drugs. Other secondary endpoints included incidence
of peri-procedural complications, procedural characteristics (ﬂuoro-
scopy time, mapping time, etc.), and number of repeat procedures.
All endpoints were pre-speciﬁed prior to unblinding the data.
Sample size and statistical analysis
At the time that this protocol was designed, there was very little data
available as to the success rates of each of the three strategies to
determine a proper sample size calculation. The study was therefore
conceived as an exploratory study. Most studies published at the
time had sample sizes of 30–40 patients and that served as the basis
for our sample size determination. The goal was to enrol a total of
STAR AF trial 134730 patients per arm (n ¼ 90). The study enrolment period was
extended to boost enrolment, and we ended up exceeding our pro-
jected sample size (n ¼ 101). Enrolment per centre was as follows:
Southlake Regional Health Centre (n ¼ 20), Ospedale Regionale di
Treviso (n ¼ 18), Montreal Heart Institute (n ¼ 16), Casa di Cura
Santa Maria (n ¼ 13), Haukeland University Hospital (n ¼ 12), Hamil-
ton Health Sciences (n ¼ 12), Royal Jubilee Hospital (n ¼ 9), and Hos-
pital General Universitario Gregorio Maran ˜o ´n( n ¼ 1). Only patients
who underwent ablation were included for analysis.
All data are reported as a mean+standard deviation for continuous
variables and number of subjects (%) for categorical variables unless
otherwise indicated. Continuous variables were compared using
ANOVA. Categorical variables were compared using the Fisher’s
exact test. Changes in AFCL were compared using paired t-test analy-
sis. Freedom from atrial arrhythmia was determined and compared
using Kaplan–Meier analysis and the log-rank test. To compare the efﬁ-
cacy of each of the three procedures, the Tukey method was applied
for multiple comparisons. For the single procedure success rate, all
patients experiencing a recurrence from 3 to 12 months were con-
sidered to have failed. For the two procedure success rate, patients
experiencing a recurrence after a second procedure on or before
the 12-month visit or patients who had a recurrence but did not
undergo repeat ablation were considered to have failed. A P-value of
,0.05 was considered signiﬁcant for all statistical determinations. All
tests of signiﬁcance were two-sided. All analysis was performed
using SAS software version 9.1.3 (SAS, Cary, NC, USA).
Results
Patient characteristics
A total of 101 patients were enrolled into the study (Figure 1).
Patients were randomized to PVI (n ¼ 33), CFE (n ¼ 34), and
PVI þ CFE (n ¼ 34). One patient randomized to PVI did not end
up undergoing ablation, so only 32 patients were available for
analysis in this group (n ¼ 100 total).
Patients enrolled in the study were predominantly male (n ¼ 74,
74%) with an age of 57+10 years. The duration of AF symptoms
pre-ablation was 7+7 years (median 4.4 years, range 1–43). Atrial
ﬁbrillation was high-burden paroxysmal in 64 patients (64%) and
persistent in 36 patients (36%). High-burden paroxysmal AF
patients had a median of 11 episodes per month (interquartile
range 3–54) with median episode duration of 10 h (interquartile
range 2–17). Patients failed 1.4+0.9 anti-arrhythmics prior to
ablation. Important co-morbidities included prior stroke/transient
ischaemic attack (5%), coronary artery disease (7%), valvular
heart disease (20%), heart failure (3%), and hypertension (45%).
Mean ejection fraction was 62+10% and the left atrial size was
42+6 mm. Characteristics of each group are detailed in Table 3
and there were no signiﬁcant differences between groups.
Mapping and ablation details
IntheCFEarm,AFwasspontaneousin14patients(41%)andinduced
in 20 (59%). Pacing alone induced AF in 10 of 20 patients, while iso-
proterenol was used in addition to pacing in the other 10 of 20
patients. The mean dose of isoproterenol used was 5+3 mcg/min
(range 1.5–10). Complex fractionated electrogram mapping was
performed with the automated mapping algorithm with a mean of
317+290 points per map (range 112–949). Complex fractionated
electrogram regions were most commonly located within the PV
antra (24 patients, 70%), on the LA roof (n ¼ 24, 70%), posterior
LA wall (n ¼ 23, 68%), at the base of the LA appendage (n ¼ 23,
68%), on the high LA septum (n ¼ 22, 65%), low LA septum (n ¼
19, 56%), CS (n ¼ 17, 50%), and the mitral valve annulus (n ¼ 14,
41%).Overall,CFEwerelesscommonlyseenintheRAvs.LA,speciﬁ-
cally the right atrial septum (n ¼ 11, 32%), crista terminalis (n ¼ 7,
21%), superior vena cava (n ¼ 7, 21%), and the cavotricuspid
isthmus (n ¼ 5, 15%). As a result of CFE ablation, AF cycle length
increased from a baseline of 180+119 to 219+46 ms (P ¼ 0.03).
Complex fractionated electrogram ablation terminated AF in 23 of
34 (68%) of patients. Speciﬁcally, AF terminated to sinus rhythm in
14 of 34 (41%) and to other regular atrial arrhythmias in 9 of 34
(26%), speciﬁcally typical right AFL (n ¼ 6) and left AFL/AT (n ¼ 3).
In all six of the patients with right AFL, and two of the left AFL/AT
patients, the regularized rhythm was successfully ablated with
restoration of sinus rhythm. In the patients who did not terminate,
sinus rhythm was restored by electrical cardioversion. At the end
of the procedure, repeat induction was attempted in 25 of 34
(73%) patients; in the other nine patients, induction was not
attempted because they had ongoing AF which did not terminate
during CFE ablation. Despite further ablation in the re-induced
patients,AFremainedinducibleintwopatients;leftAFL/ATremained
inducible in six patients; and typical right AFL in one patient. Only
0.4+1.0 PVs (median 0, range 0–3) were isolated as a result of
CFE ablation.
In the PVI arm, 10 of 32 (31%) of patients were spontaneously in
AF at the start of the procedure. Isolation of all PV antra was
achieved in 94% (30 of 32) of patients. In the remaining two
patients, three of four PVs were successfully isolated. At the end
of PVI ablation, six patients had ongoing AF which required cardi-
oversion back to sinus rhythm.
In the PVI þ CFE arm, isolation of all PV antra was achieved in
94% (32 of 34) of patients. In the remaining two patients, three
of four PVs were successfully isolated. At the end of PV isolation,
AF was ongoing in 14 (41%) patients and induced in another
12 (35%) patients with the use of pacing and isoproterenol
Figure 1 Study patient randomization ﬂowchart. A total of 101
patients were enrolled in the study. Only 100 underwent abla-
tion, with one patient in the PVI arm not undergoing the ablation
procedure.
A. Verma et al. 1348(dose 7+4 mcg/min). Thus, 26 patients (76%) received adjuvant
CFE ablation after PVI. Automated CFE mapping was performed
with a mean of 205+261 points per map (range 103–1094).
Complex fractionated electrogram regions were mostly located
at the base of the LA appendage (18 patients, 69%), on the low
LA septum (n ¼ 18, 69%), high LA septum (n ¼ 17, 65%), CS
(n ¼ 16, 61%), mitral valve annulus (n ¼ 15, 58%), the LA roof
(n ¼ 11, 42%), and the posterior wall (n ¼ 5, 19%). Right atrial
sites were less common, speciﬁcally the right atrial septum (n ¼
8, 31%), crista terminalis (n ¼ 6, 23%), and the cavotricuspid
isthmus (n ¼ 5, 19%). Adjuvant CFE ablation prolonged AF cycle
length from a baseline of 215+146 to 235+135 ms (P ¼ 0.04).
Atrial ﬁbrillation terminated in 19 of 26 (73%) of patients: 11 to
sinus, 5 to right AFL, and 3 to left AFL/AT. In four of the patients
with right AFL and one of the left AFL/AT patients, the regularized
rhythm was successfully ablated with restoration of sinus rhythm.
The others were cardioverted. Atrial ﬁbrillation re-induction was
attempted in the 15 of the 19 patients who terminated with abla-
tion. Despite further ablation in the re-induced patients, AF
remained inducible in four patients; left AFL/AT remained inducible
in ﬁve patients; and typical right AFL in one patient.
Mapping, procedural, ﬂuoroscopy, and RF times for ﬁrst pro-
cedures in each arm are presented in Table 4. In spite of the com-
bination of two approaches in PVI þ CFE, ﬂuoroscopy times were
similar among the three groups. There was a trend towards
shorter procedure time (P ¼ 0.11) and less mapping time (P ¼
0.09) in the PVI arm compared with the other two arms. As
expected, there was also a trend towards more RF time in the
PVI þ CFE group, but this did not reach statistical signiﬁcance
(P ¼ 0.07). Representative maps of each of the three arms are pre-
sented in Figure 2A–C.
Outcomes
At the 12-month follow-up, 94% of all enrolled patients were off
anti-arrhythmic medications. Among patients considered to have
a successful post-ablation outcome, 96% were off anti-arrhythmics.
Patients with a successful post-ablation outcome who were still on
anti-arrhythmics were evenly distributed across the three arms,
speciﬁcally two patients (6%) in PVI þ CFE, one patient (3%) in
PVI, and one patient (3%) in CFE.
After one procedure, PVI þ CFE had the highest freedom from
AF (74%) compared with PVI (48%) and CFE (29%) (P ¼ 0.004)
(Figure 3A). The outcome for PVI þ CFE was signiﬁcantly better
than either PVI (P ¼ 0.03) or CFE (P , 0.001) alone. After two
procedures, PVI þ CFE still had the highest freedom from AF
at 1 year (88%) compared with PVI (68%) and CFE (38%)
(P ¼ 0.001), with PVI þ CFE still signiﬁcantly better than either
PVI (P ¼ 0.04) or CFE (P , 0.001) alone (Figure 4A).
...............................................................................................................................................................................
Table 3 Study patient characteristics
CFE (n 5 34) PVI (n 5 32) PVI 1 CFE (n 5 34) P-value
Age (years) 57+95 5 +11 59+10 0.32
Male 25 (74%) 24 (75%) 25 (74%) 0.41
Paroxysmal 21 (62%) 21 (66%) 22 (65%) 0.75
Persistent 13 (38%) 11 (34%) 12 (35%) 0.70
AF duration (years) 6.4+6.0 6.4+6.6 7.6+9.4 0.18
Number failed AAD 1.4+0.8 1.4+0.8 1.4+0.9 0.52
Stroke/TIA 2 (6%) 1 (3%) 2 (6%) 0.44
Hypertension 15 (44%) 16 (50%) 14 (41%) 0.20
Body mass index (kg/m
2)3 1 +10 29+92 9 +9 0.36
Coronary disease 3 (9%) 1 (3%) 3 (9%) 0.23
Valvular disease 6 (18%) 6 (19%) 8 (23%) 0.25
Heart failure 1 (3%) 2 (6%) 0 (0%) 0.15
Ejection fraction 64+10% 62+7% 59+12% 0.38
Left atrial size (mm) 41+64 3 +54 1 +6 0.21
AF, atrial ﬁbrillation; AAD, anti-arrhythmic drugs; TIA, transient ischaemic attack.
...............................................................................................................................................................................
Table 4 Procedural characteristics (ﬁrst procedure)
CFE PVI PVI 1 CFE P-value
Procedural duration (min) 224+68 181+74 225+68 0.11
Mapping time (min) 39+18 29+21 41+20 0.09
Fluoroscopy time (min) 56+28 58+27 60+34 0.29
Radiofrequency time (min) 63+33 64+42 78+50 0.07
STAR AF trial 1349When the combined endpoint of freedom from AF/AFL/AT was
considered, PVI þ CFE still had the highest success rate (74%)
compared with PVI (45%) and CFE (24%) (P ¼ 0.003) after one
procedure (Figure 3B). The outcome for PVI þ CFE was signiﬁ-
cantly better than either PVI (P ¼ 0.02) or CFE (P , 0.001)
alone. After two procedures, PVI þ CFE had a success rate of
88% compared with 68% for PVI and 32% for CFE (P ¼ 0.001).
Again, the outcome for PVI þ CFE was signiﬁcantly better than
the outcome of PVI (P ¼ 0.04) or CFE (P , 0.001) alone
(Figure 4B).
When the high-burden paroxysmal and persistent subgroups
were analysed separately, PVI þ CFE had a signiﬁcantly better
outcome compared with CFE at 1 year after one procedure for
both freedom from AF (P ¼ 0.002) and freedom from AF/AFL/
AT (P ¼ 0.001) (Figure 5). PVI þ CFE also had a signiﬁcantly
higher success rate compared with PVI in the persistent subgroup
Figure 2 (A–C) Representative left atrial (LA) electroanatomical maps illustrating the three ablation strategies used in the study. On the left
side are panels showing posterior or modiﬁed posterior views of the LA and on the right side are panels showing the anterior view of the LA.
(A) Pulmonary vein isolation (PVI) strategy. Brown points represent points of radiofrequency (RF) energy application around the four pulmonary
venous (PV) antra with the endpoint of electrical isolation of all four PV antra. (B) Complex fractionated electrogram (CFE) strategy. The
colour-coded map shows regions of highly fractionated atrial electrograms during AF (shown in red and white colours, equivalent to a local
cycle length ,120 ms). The brown points represent applications of RF energy over CFE regions with the endpoint of AF termination/non-
inducibility. (C) Combined procedure of PVI followed by CFE ablation. The brown points illustrate ablation points applied around all four
PV antra with the endpoint of electrical isolation. The colour-coded map shows regions of highly fractionated electrograms (red and white)
that were mapped during AF post-PVI. The green points represent RF energy applications to CFE regions after PVI with the endpoint of AF
termination/non-inducibility.
A. Verma et al. 1350(P ¼ 0.03). In the high-burden paroxysmal subgroup, there was no
statistically signiﬁcant beneﬁt of PVI þ CFE over PVI alone (P ¼
0.14). However, the relative beneﬁt of PVI þ CFE over PVI alone
was similar in both subgroups (interaction P ¼ 0.87).
Repeat procedures
A mean of 1.2+0.4 procedures were done per patient. Repeat
procedures were performed 5+2 months after the ﬁrst pro-
cedure. PVI þ CFE had the lowest incidence of repeat procedures.
Figure 3 (A and B) Kaplan–Meier curves depicting time to ﬁrst atrial ﬁbrillation (AF) recurrence (A) and time to ﬁrst AF, atrial ﬂutter (AFL), or
atrial tachycardia (AT) recurrence (B) after one procedure in the pulmonary vein isolation (PVI) strategy, the complex fractionated electrogram
(CFE) strategy, and the combined strategy of PVI followed by CFE ablation (PVI þ CFE). PVI þ CFE had a signiﬁcantly higher freedom from AF
after one procedure (74%) compared with either PVI (48%) or CFE (29%) alone (log-rank P ¼ 0.004). PVI þ CFE also had a signiﬁcantly higher
freedom from AF/AFL/AT after one procedure (74%) compared with either PVI (45%) or CFE (24%) alone (log-rank P ¼ 0.003). Post hoc analysis
comparing individual groups is detailed in text. Ninety-six percent of patients who were considered successful were off anti-arrhythmic medications
and were evenly distributed among groups (also detailed in text). Numbers at risk for each group are indicated below the x-axis.
STAR AF trial 1351There were signiﬁcantly more repeat procedures in the CFE arm
(47%, n ¼ 16) vs. PVI (31%, n ¼ 10) or PVI þ CFE (15%, n ¼ 5)
(P ¼ 0.01). The percentage of patients undergoing repeat pro-




forations occurred, resulting in cardiac tamponade. Four patients had
Figure 4 (A and B) Kaplan–Meier curves depicting time to ﬁrst atrial ﬁbrillation (AF) recurrence (A) and time to ﬁrst AF, atrial ﬂutter (AFL), or
atrial tachycardia (AT) recurrence (B) after two procedures in the pulmonary vein isolation (PVI) strategy, the complex fractionated electrogram
(CFE) strategy, and the combined strategy of PVI followed by CFE ablation (PVI þ CFE). For the endpoint of AF (A), the combined strategy of
pulmonary vein isolation followed by complex fractionated electrogram ablation (PVI þ CFE) had a signiﬁcantly higher freedom from AF (88%)
compared with either pulmonary vein isolation (PVI) (68%) or complex fractionated electrogram ablation (CFE) (38%) alone (P ¼ 0.001). For
the endpoint of AF/AFL/AT, PVI þ CFE still had the highest freedom from arrhythmia (88%) compared with PVI (68%) or CFE (32%) alone
(P ¼ 0.001). Post hoc analysis comparing individual groups is detailed in text. Numbers at risk for each group are indicated below the x-axis.
A. Verma et al. 1352minor bleeding related to the procedure (three femoral hematomas
and one hematuria from urinary catheter insertion), none requiring
transfusion or intervention. One patient had a vascular complication
(pseudoaneurysm) that was managed with local injection, and one
patient had minor (30%) PV stenosis of one vein (left inferior).
TherewerenooccurrencesofsigniﬁcantPVstenosis,emboliccompli-
cation, stroke, atrial-esophageal ﬁstula, or death.
Discussion
Main ﬁndings
This prospective, randomized, multicentre study demonstrates that
ablation of CFE alone in high-burden paroxysmal/persistent AF
patients has a low success rate when compared with PVI or
PVI þ CFE after one or two procedures. In spite of using auto-
mated, validated CFE mapping software resulting in an acute ter-
mination rate of .60%, CFE resulted in a success rate less than
50% and also resulted in the highest number of repeat ablation
procedures. In contrast, when CFE was added to PVI, the
success rate was superior to either strategy alone after one or
Figure 5 Percentage of patients free from either atrial ﬁbrillation (AF) or AF, atrial ﬂutter (AFL) or atrial tachycardia (AT) in the high-burden
paroxysmal and persistent subgroups after one procedure. The freedom from arrhythmia was highest in the combined pulmonary vein isolation
followed by complex fractionated electrogram ablation arm (PVI þ CFE) in both the high-burden paroxysmal and persistent subgroups.
However, the difference between PVI þ CFE and pulmonary vein isolation alone (PVI) was not statistically signiﬁcant in the high-burden par-
oxysmal subgroup (P ¼ 0.14), whereas it was statistically signiﬁcant in the persistent subgroup (P ¼ 0.03). PVI þ CFE had a signiﬁcantly higher
success rate compared with CFE in both subgroups for both endpoints.
................................................................................
Table 5 Study adverse events
CFE PVI PVI 1 CFE
Cardiac tamponade 1 1 0
Minor bleeding
a 11 2
Major bleeding 0 0 0
Vascular complication
b 01 0
Embolic complication 0 0 0
Mild PV stenosis (,50%) 0 1 0
Severe PV stenosis (.50%) 0 0 0
Death 0 0 0
aThree femoral hematomas, one hematuria.
bOne femoral pseudoaneurysm.
Figure 6 Percentage of patients undergoing repeat ablation
procedures in each of the three arms of the study. The combined
arm of pulmonary vein isolation followed by complex fractio-
nated electrogram ablation (PVI þ CFE) had the lowest percen-
tage of patients undergoing repeat procedures (15%). This
difference was statistically signiﬁcant compared with the
complex fractionated electrogram (CFE) arm alone (P ¼ 0.008)
which had 47% of patients undergoing repeat ablation. There
was only a trend towards signiﬁcance compared with the pul-
monary vein isolation (PVI) arm alone (P ¼ 0.07), which had
31% of patient undergoing repeat ablation. There was no statisti-
cal difference between the percentage of repeat procedures in
the PVI and CFE arms alone (P ¼ 0.21).
STAR AF trial 1353two procedures. Furthermore, PVI þ CFE reached higher success
rates with fewer repeat ablation procedures compared with the
other two strategies. Thus, CFE ablation guided by automated
mapping software may have an additive beneﬁt over PVI alone,
but does not sufﬁce as an ablation strategy in and of itself. This
study is the ﬁrst randomized, multicentre trial to compare these
techniques using a consistent, validated approach to CFE ablation
in a high-burden paroxysmal/persistent AF population. It is also
unique since it utilized the same ablation strategy for the repeat
procedure as was used for the initial ablation.
Utility of complex fractionated
electrograms ablation alone
A substantial amount of information suggests that CFE may be an
important target for AF ablation. From early animal and human
experiments, it was found that atrial regions exhibiting very rapid
activation may represent critical rotors responsible for maintaining
AF.
16,17 Furthermore, regions demonstrating very fragmented
potentials, to the point of almost continuous baseline activity,
may represent pivot points or regions of very slow conduction
responsible for continued ﬁbrillatory conduction.
3 Complex frac-
tionated electrograms may also be generated by local changes in
autonomic tone and may therefore represent sites of autonomic
plexi in the atrium.
18 However, electrogram fractionation may
also occur as a result of tissue anisotropy, wavefront collision, or
wave break, which can be transient phenomena that change over
time.
16,19 Signals that meet the speciﬁc deﬁnition of CFE may
exhibit some transient activity, potentially affected by global
AFCL. However, studies have shown that CFE are both spatially
and temporally stable, particularly when observed/analysed over
a short period of time (2–8 s) as is done with automated
mapping algorithms.
20,21
In the clinical setting, one investigator has been able to achieve
very good success rates by exclusively targeting CFE for AF abla-
tion,
4,22 but these results have not been replicated by others.
5
One potential limitation of the latter study is that CFE regions
were identiﬁed by visual interpretation alone, and this can be chal-
lenging given that CFE regions are often low voltage and difﬁcult to
localize if not observed over a few seconds. Automated CFE
mapping, as employed in the current study, offers more objective
identiﬁcation and ablation of CFE regions.
7 Yet, in spite of this,
the success rate of CFE alone was still low even after two pro-
cedures. This is not surprising given the known importance of trig-
gers for AF originating from predominantly PV sites.
2 Although
CFE ablation may eliminate the substrate required for chronic
AF maintenance, it does not eliminate the triggers that can initiate
paroxysms of AF and AT/AFL. We had a very low rate of incidental
PV isolation as a result of CFE ablation (0.4 PVs isolated per
patient).
It is interesting that the low success rate occurred even though
the rate of acute procedural AF termination was high (more than
65%), with a substantial prolongation of AFCL, both of which have
been shown previously to correlate with long-term freedom from
AF.
6 One possible explanation is that acute termination may not be
predictive of post-ablation success.
23 Another may be that the
changes in AFCL and acute termination may demonstrate
successful alteration of the AF substrate, but this may not be sufﬁ-
cient unless the triggers (PV and non-PV) have been concomitantly
eliminated.
Utility of complex fractionated
electrograms as an adjuvant strategy
Previous data have suggested that when elimination of triggers for
AF (PVI) is combined with ablation of the substrate required for AF
maintenance, the outcome may be improved compared with either
approach alone in a variety of AF patients.
7,11,24,25 However, the
data on this have been mixed, with some reports suggesting no
beneﬁt of additional CFE ablation,
9 or variable beneﬁt depending
on the speciﬁc AF population targeted.
10 For example, persistent
patients may beneﬁt from such additional ablation, whereas parox-
ysmals may not.
24 Again, part of the variability in outcomes may be
due to the fact that most of these studies ablated CFE by visual
identiﬁcation alone, without the use of more objective, automated
mapping methods. In two studies using automated CFE mapping,
there was a promising beneﬁt of adjuvant CFE ablation combined
with PVI compared with PVI alone, but neither study was a ran-
domized comparison.
7,8 Another potential explanation is that in
this study, biatrial CFE ablation was performed, whereas only the
LA was included in the previous data.
9 Furthermore, our study
focused on a high-burden AF population, not just a lone paroxys-
mal population,
10 which may explain why our outcomes differed.
In the present study, the combination of PVI þ CFE had the best
outcome compared with either of the other two arms in a popu-
lation of high-burden paroxysmal/persistent AF patients after
either one or two procedures. Furthermore, PVI þ CFE achieved
this success with a smaller number of repeat procedures compared
with either of the other two arms. Although there is data
suggesting that even lone, paroxysmal AF patients have abnormal
atrial substrate changes which may need to be targeted,
14 there
was a trend but no statistically signiﬁcant beneﬁt of PVI þ CFE
over PVI alone in the high-burden paroxysmal AF subgroup. Pul-
monary vein isolation alone may be considered a cornerstone of
AF ablation,
1 but it may not be sufﬁcient for higher-burden AF
populations. In our study, the one and two procedural success
rates for PVI alone were modest, consistent with other single-
centre studies showing success rates of 50–75% with 25–50%
of these patients typically requiring more than one procedure.
6,9,26
Thus, in spite of the fact that the same incidence of PV isolation
was achieved in both the PVI and PVI þ CFE arms (94%), the com-
bined arm had a better outcome. In the PVI þ CFE arm, the better
outcome did seem to correlate with a high rate of procedural ter-
mination of AF (73%) and AFCL prolongation, in contrast to the
CFE arm. This is likely because the combined arm not only suc-
cessfully modiﬁed the substrate, but also eliminated the triggers
for AF.
This study was unique in that all repeat ablation procedures
were done using the same approach as the initial randomized strat-
egy, in contrast to prior data where repeat procedures were per-
formed according to the discretion of the operator.
9 Thus, the two
procedural success rate of this study is a more accurate reﬂection
of the efﬁcacy of each strategy and also demonstrates how one
A. Verma et al. 1354strategy may minimize the number of repeat procedures for a
patient compared with other approaches.
Finally, any advantage of combined ablation in terms of outcome
could be offset by the additional mapping and ablation time.
Although the mapping and procedural times for the combined
approach were somewhat longer than the PVI approach alone,
the differences were not statistically signiﬁcant, which is consistent
with the previous data.
7 The fact that the times for PVI þ CFE
were very similar to CFE alone may also reﬂect a learning curve
for operators who are more used to performing PVI. Also, the
use of automated CFE mapping software may have prevented
the additional time for CFE ablation from being excessive.
Clinical implications
This study is the ﬁrst multicentre, randomized trial to compare
trigger and substrate-based ablation strategies in a high-burden
paroxysmal/persistent AF population. The study is also unique in
that both initial and repeat ablations involved the same randomized
strategy and CFE ablation was guided by objective, validated, auto-
mated mapping methods. The results show that CFE ablation
coupled with PVI may offer a better outcome with fewer repeat
procedures compared with PVI or CFE alone. Furthermore, the
beneﬁt can be obtained without excessively prolonging mapping
or ablation times. Pulmonary vein isolation alone is moderately
effective in this population as a lone strategy, whereas CFE alone
results in a poor long-term outcome with signiﬁcantly more
repeat procedures. These results not only build upon the knowl-
edge gained from earlier, single-centre studies, but also serve as
the basis for further, larger-scale trials. These results also show
that consistent, successful results from AF ablation can be obtained
across a spectrum of operators working in medium-volume
centres that do not represent the usual high-volume, extensively
published centres.
Study limitations
The study is limited by the sample sizes of each arm, although clear,
signiﬁcant differences were seen between all arms, even after two
procedures. To more accurately assess the difference between the
PVI and PVI þ CFE strategy, a much larger-scale study would have
to be performed. Another potential limitation is that the study
included a mixed AF population of both paroxysmals and persist-
ents. Previous studies, including this one, have suggested that adju-
vant CFE ablation may have a larger impact in persistent AF.
However, at the time the protocol was conceived, it was unclear
if PVI alone was sufﬁcient for all paroxysmal AF. Data had shown
that adjuvant ablation beyond PVI alone was effective in paroxys-
mal AF.
6,7 Data have also shown that even paroxysmal AF patients
with greater amounts of arrhythmia have abnormal atrial substrate
changes which may need to be targeted in addition to PV trig-
gers.
7,14 The paroxysmal group in this study represented one
with a high burden of disease and very prolonged AF episodes
(median 10 h/episode). However, the difference between PVI þ
CFE and PVI was not statistically signiﬁcant in the high-burden par-
oxysmal subgroup. This study also did not include long-standing
persistent AF patients (more than 1 year), which limits the applica-
bility of our results. The use of isoproterenol in a minority of
patients (10 in CFE arm and 12 in PVI þ CFE) may have affected
AFCL, although the baseline CL of 180 ms was not rapid compared
with prior publications.
6,7 Furthermore, it is unlikely to have
affected CFE given that the automated algorithm averages CFE
analysis over several seconds, helping to identify stable, consistent
CFE sites vs. transient regions.
20 Atrial ﬁbrillation cycle length may
also have been affected by CS ablation, however, CS ablation was
done after all LA ablation was complete, and most of the change in
AFCL was seen prior to CS ablation. Atrial ﬁbrillation cycle length
was also not an endpoint of this study. Finally, this study did not
systematically evaluate the efﬁcacy of linear lesions either alone
or in combination with other strategies. Whether linear ablation
would further improve outcomes or not is a question that requires
further, randomized study.
Conclusions
In high-burden paroxysmal/persistent AF, PVI þ CFE has the
highest freedom from AF vs. PVI or CFE alone after one or two
procedures. Complex fractionated electrogram alone has the
lowest one and two procedure success rates with a higher inci-
dence of repeat procedures.
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